Status:
COMPLETED
Use of an In Vivo Optical Probe to Discriminate Benign From Malignant Thyroid Nodules
Lead Sponsor:
Boston Medical Center
Collaborating Sponsors:
Fraunhofer USA
Conditions:
Cancer
Thyroid
Eligibility:
All Genders
18-80 years
Brief Summary
This study will investigate the usefulness of an optical probe in the differentiation of thyroid cancer from normal thyroid tissue in a thyroidectomy specimen. This is the next step in the research th...
Detailed Description
Background: Thyroid cancer is the most common endocrine malignancy. The current gold standard, fine-needle aspiration (FNA) biopsy, yields approximately 10-25% of indeterminate results, leading to pat...
Eligibility Criteria
Inclusion
- Subjects undergoing thyroid biopsy for thyroid nodules, thyroid cancer, and thyroid goiter with nodules. Only those patients requiring sampling under established standard of care criteria and already scheduled to undergo biopsy for clinical purposes will undergo optical biopsy at the same time as their physical biopsy.
Exclusion
- Subjects with nodules smaller than 1 cm, infectious diseases, on medication (such as coumadin) that may interfere with optical readings
Key Trial Info
Start Date :
June 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01401855
Start Date
June 1 2011
End Date
June 1 2014
Last Update
June 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Medical Center
Boston, Massachusetts, United States, 02118